Outlook Therapeutics Inc (OTLK): It was compliant in Europe and Europe is...

Send PM Follow Ignore

Followers	17
Posts	3900
Boards Moderated	0
Alias Born	10/04/2006

techno53

Re: shurtha2000 post# 1474

Tuesday, 05/26/2026 9:40:42 AM

Tuesday, May 26, 2026 9:40:42 AM

It was compliant in Europe and Europe is much stricter than FDA. We should be glad Trump fired those 2 clowns as they were the hold up on new drugs.

Keep Last Read

Next 10 Prev Next

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

Detailed Quote

Recent OTLK News

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 06/02/2026 01:31:05 AM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/02/2026 01:30:12 AM
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 06/01/2026 09:00:43 PM
Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/01/2026 09:00:21 PM
Form 8-K - Current report • Edgar (US Regulatory) • 06/01/2026 01:15:32 PM
Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg) • GlobeNewswire Inc. • 06/01/2026 12:46:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 05/29/2026 08:30:49 PM
Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/29/2026 12:30:23 PM
Form 8-K - Current report • Edgar (US Regulatory) • 05/28/2026 09:09:53 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/27/2026 07:29:11 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/27/2026 07:24:20 PM
Form 8-K - Current report • Edgar (US Regulatory) • 05/26/2026 11:15:41 AM
Outlook Therapeutics Wins Appeal Following Formal Dispute Resolution Process for ONS-5010/LYTENAVA™ (bevacizumab-vikg) • GlobeNewswire Inc. • 05/26/2026 11:00:00 AM
Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2026 09:03:14 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2026 08:31:12 PM
Outlook Therapeutics Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 05/15/2026 08:05:00 PM
Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/13/2026 09:12:56 PM
Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2026 08:36:26 PM
Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 05/07/2026 08:24:31 PM
Form 8-K - Current report • Edgar (US Regulatory) • 04/23/2026 08:30:39 PM
Outlook Therapeutics Announces Closing of $5.0 Million Registered Direct Offering • GlobeNewswire Inc. • 04/23/2026 08:05:00 PM
Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 04/23/2026 11:30:17 AM
Outlook Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 04/21/2026 08:15:44 PM
Outlook Therapeutics Completes Federal Dispute Resolution (FDR) Meeting with FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg) • GlobeNewswire Inc. • 04/21/2026 01:05:00 PM

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Detailed Quote

Recent OTLK News

More OTLK News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent OTLK News

Go Ad-Free